The Prognostic Impact of Tumor Size and BRAF Mutational Status in Middle Eastern Differentiated Thyroid Cancer
Authors' conclusion
Tumor size is an independent predictor of EFS in Middle Eastern patients with DTC, regardless of BRAF mutational status.
Study context
- Population
- Consecutive Middle Eastern patients treated surgically for differentiated thyroid cancer (DTC)
- Participants
- 1,709 patients
- Exposure
- Tumor size by BRAF mutation status
- Outcome
- Event-free survival (EFS)
Methodological detailsconsecutive patients
- Consecutive patients
Main finding
As reported in the abstract
EFS
- Tumor size >4 cm and BRAF mutation were each associated with event-free survival (EFS) on univariate analysis
- Larger tumor size was an independent predictor of EFS (Group 3 vs Group 1), irrespective of BRAF status
- Within BRAF-mutant tumors, larger tumor size was still an independent predictor of EFS (Group 4 vs Group 2)
Observational data: associations, not effects.
Further findings
Clinicopathologic associations of tumor size >4 cm
- Tumor size >4 cm associated with older age, male gender, bilateral tumors, extrathyroidal extension, lymphovascular invasion, advanced stage and persistent/recurrent disease
- Tumor size inversely associated with BRAF mutation
Original publication
The Prognostic Impact of Tumor Size and BRAF Mutational Status in Middle Eastern Differentiated Thyroid Cancer. J Clin Endocrinol Metab. Published 18 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →